Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.

Xu, Manyi; Hao, Yue; Zeng, Xiaohong; Si, Jinfei; Song, Zhengbo

Xu, Manyi; Hao, Yue; Zeng, Xiaohong; Si, Jinfei; Song, Zhengbo.

Afiliación

Xu M; The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Hao Y; Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Zeng X; The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Si J; Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Song Z; Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.

J Thorac Dis ; 15(4): 1648-1657, 2023 Apr 28.

Article en En | MEDLINE | ID: mdl-37197488

Palabras clave

Non-small cell lung cancer (NSCLC); efficacy; immune checkpoint inhibitors (ICIs); immunotherapy beyond progression (IBP)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Thorac Dis Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google